Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulax vs Botox in Cervical Dystonia
NCT04171258Phase 1Completed
- Sponsor
- Hugel
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of botulinum toxin type A in cervical dystonia (CD) (2 arms), sponsored by Hugel. Primary endpoints: Rate of Adverse Events at 12 weeks and Change From Baseline in the Total Score of the Toronto Western Spasmodic Torticollis Rating Scale at 12 weeks. Started May 2020; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on NCT04171258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171258.